Sipuleucel-T immunotherapy for castration-resistant prostate cancer. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF, IMPACT Study Investigators (2010) N Engl J Med 363: 411-22 Regulation of net hepatic glucose uptake in vivo. Pagliassotti MJ, Cherrington AD (1992) Annu Rev Physiol 54: 847-60 Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. Hainsworth JD, Sosman JA, Spigel DR, Edwards DL, Baughman C, Greco A (2005) J Clin Oncol 23: 7889-96 BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H, Cheverton P, Chen D, Peterson AC, Carson WE, O'Day SJ (2012) J Clin Oncol 30: 34-41 High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. O'Neil BH, Allen R, Spigel DR, Stinchcombe TE, Moore DT, Berlin JD, Goldberg RM (2007) J Clin Oncol 25: 3644-8 Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. McDermott DF, Sosman JA, Gonzalez R, Hodi FS, Linette GP, Richards J, Jakub JW, Beeram M, Tarantolo S, Agarwala S, Frenette G, Puzanov I, Cranmer L, Lewis K, Kirkwood J, White JM, Xia C, Patel K, Hersh E (2008) J Clin Oncol 26: 2178-85 Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma. Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI (1994) J Clin Oncol 12: 1553-60 Phase III, randomized study of gemcitabine and oxaliplatin versus gemcitabine (fixed-dose rate infusion) compared with gemcitabine (30-minute infusion) in patients with pancreatic carcinoma E6201: a trial of the Eastern Cooperative Oncology Group. Poplin E, Feng Y, Berlin J, Rothenberg ML, Hochster H, Mitchell E, Alberts S, O'Dwyer P, Haller D, Catalano P, Cella D, Benson AB (2009) J Clin Oncol 27: 3778-85 Phase I/II trial of tremelimumab in patients with metastatic melanoma. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, Ribas A (2009) J Clin Oncol 27: 1075-81 Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. Tolcher AW, Sarantopoulos J, Patnaik A, Papadopoulos K, Lin CC, Rodon J, Murphy B, Roth B, McCaffery I, Gorski KS, Kaiser B, Zhu M, Deng H, Friberg G, Puzanov I (2009) J Clin Oncol 27: 5800-7 Prolonged administration of low-dose, infusional etoposide in patients with etoposide-sensitive neoplasms: a phase I/II study. Thompson DS, Hainsworth JD, Hande KR, Holzmer MC, Greco FA (1993) J Clin Oncol 11: 1322-8 Bioavailability of low-dose oral etoposide. Hande KR, Krozely MG, Greco FA, Hainsworth JD, Johnson DH (1993) J Clin Oncol 11: 374-7 Phase I study of intravenous vascular endothelial growth factor trap, aflibercept, in patients with advanced solid tumors. Lockhart AC, Rothenberg ML, Dupont J, Cooper W, Chevalier P, Sternas L, Buzenet G, Koehler E, Sosman JA, Schwartz LH, Gultekin DH, Koutcher JA, Donnelly EF, Andal R, Dancy I, Spriggs DR, Tew WP (2010) J Clin Oncol 28: 207-14 Eastern Cooperative Oncology Group Phase I trial of protracted venous infusion fluorouracil plus weekly gemcitabine with concurrent radiation therapy in patients with locally advanced pancreas cancer: a regimen with unexpected early toxicity. Talamonti MS, Catalano PJ, Vaughn DJ, Whittington R, Beauchamp RD, Berlin J, Benson AB (2000) J Clin Oncol 18: 3384-9 Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. Demetri GD, Chawla SP, von Mehren M, Ritch P, Baker LH, Blay JY, Hande KR, Keohan ML, Samuels BL, Schuetze S, Lebedinsky C, Elsayed YA, Izquierdo MA, Gómez J, Park YC, Le Cesne A (2009) J Clin Oncol 27: 4188-96 Vasodilation during systemic tyramine administration response. Goldstein DS, Holmes C, Jacob G, Costa F, Vincent S, Robertson D, Biaggioni I (2004) Circulation 109: E17-8 Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phosphatidylinositol 3-kinase/AKT kinase. Kupatt C, Hinkel R, Lamparter M, von Brühl ML, Pohl T, Horstkotte J, Beck H, Müller S, Delker S, Gildehaus FJ, Büning H, Hatzopoulos AK, Boekstegers P (2005) Circulation 112: I117-22 Nitroglycerin induces late preconditioning against myocardial infarction in conscious rabbits despite development of nitrate tolerance. Hill M, Takano H, Tang XL, Kodani E, Shirk G, Bolli R (2001) Circulation 104: 694-9 Neurovascular dissociation with paradoxical forearm vasodilation during systemic tyramine administration. Jacob G, Costa F, Vincent S, Robertson D, Biaggioni I (2003) Circulation 107: 2475-9 Cardiac rupture, mortality and the timing of thrombolytic therapy: a meta-analysis. Honan MB, Harrell FE, Reimer KA, Califf RM, Mark DB, Pryor DB, Hlatky MA (1990) J Am Coll Cardiol 16: 359-67 Hemodynamic, ventilatory, and biochemical responses of panic patients and normal controls with sodium lactate infusion and spontaneous panic attacks. Gaffney FA, Fenton BJ, Lane LD, Lake CR (1988) Arch Gen Psychiatry 45: 53-60 Importance of the route of intravenous glucose delivery to hepatic glucose balance in the conscious dog. Adkins BA, Myers SR, Hendrick GK, Stevenson RW, Williams PE, Cherrington AD (1987) J Clin Invest 79: 557-65 Murine double nullizygotes of the angiotensin type 1A and 1B receptor genes duplicate severe abnormal phenotypes of angiotensinogen nullizygotes. Tsuchida S, Matsusaka T, Chen X, Okubo S, Niimura F, Nishimura H, Fogo A, Utsunomiya H, Inagami T, Ichikawa I (1998) J Clin Invest 101: 755-60 Considerations and challenges in defining optimal iron utilization in hemodialysis. Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, Dialysis Advisory Group of the American Society of Nephrology (2015) J Am Soc Nephrol 26: 1238-47 Basal hepatic glucose production is regulated by the portal vein insulin concentration. Sindelar DK, Chu CA, Venson P, Donahue EP, Neal DW, Cherrington AD (1998) Diabetes 47: 523-9 Portal venous 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion overcomes hyperinsulinemic suppression of endogenous glucose output. Camacho RC, Pencek RR, Lacy DB, James FD, Donahue EP, Wasserman DH (2005) Diabetes 54: 373-82 Role of gluconeogenesis in sustaining glucose production during hypoglycemia caused by continuous insulin infusion in conscious dogs. Frizzell RT, Hendrick GK, Biggers DW, Lacy DB, Donahue DP, Green DR, Carr RK, Williams PE, Stevenson RW, Cherrington AD (1988) Diabetes 37: 749-59 Portal serotonin infusion and glucose disposal in conscious dogs. Moore MC, Geho WB, Lautz M, Farmer B, Neal DW, Cherrington AD (2004) Diabetes 53: 14-20 Interaction between insulin and glucose-delivery route in regulation of net hepatic glucose uptake in conscious dogs. Adkins-Marshall BA, Myers SR, Hendrick GK, Williams PE, Triebwasser K, Floyd B, Cherrington AD (1990) Diabetes 39: 87-95 Inhalation of human insulin (exubera) augments the efficiency of muscle glucose uptake in vivo. Edgerton DS, Cherrington AD, Williams P, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Kuo MC, Strack TR (2006) Diabetes 55: 3604-10 The effects of differing insulin levels on the hormonal and metabolic response to equivalent hypoglycemia in normal humans. Davis SN, Goldstein RE, Jacobs J, Price L, Wolfe R, Cherrington AD (1993) Diabetes 42: 263-72 5-Aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside causes acute hepatic insulin resistance in vivo. Pencek RR, Shearer J, Camacho RC, James FD, Lacy DB, Fueger PT, Donahue EP, Snead W, Wasserman DH (2005) Diabetes 54: 355-60 Effects of insulin deficiency or excess on hepatic gluconeogenic flux during glycogenolytic inhibition in the conscious dog. Edgerton DS, Cardin S, Pan C, Neal D, Farmer B, Converse M, Cherrington AD (2002) Diabetes 51: 3151-62 Small amounts of fructose markedly augment net hepatic glucose uptake in the conscious dog. Shiota M, Galassetti P, Monohan M, Neal DW, Cherrington AD (1998) Diabetes 47: 867-73 Inhalation of insulin (Exubera) is associated with augmented disposal of portally infused glucose in dogs. Edgerton DS, Neal DW, Scott M, Bowen L, Wilson W, Hobbs CH, Leach C, Sivakumaran S, Strack TR, Cherrington AD (2005) Diabetes 54: 1164-70 Exercise-induced changes in insulin and glucagon are not required for enhanced hepatic glucose uptake after exercise but influence the fate of glucose within the liver. Pencek RR, James FD, Lacy DB, Jabbour K, Williams PE, Fueger PT, Wasserman DH (2004) Diabetes 53: 3041-7 Nonesterified fatty acids and hepatic glucose metabolism in the conscious dog. Moore MC, Satake S, Lautz M, Soleimanpour SA, Neal DW, Smith M, Cherrington AD (2004) Diabetes 53: 32-40 A comparison of the effects of selective increases in peripheral or portal insulin on hepatic glucose production in the conscious dog. Sindelar DK, Balcom JH, Chu CA, Neal DW, Cherrington AD (1996) Diabetes 45: 1594-604 Phase I study of topotecan administered as a 21-day continous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Frangoul H, Ames MM, Mosher RB, Reid JM, Krailo MD, Seibel NL, Shaw DW, Steinherz PG, Whitlock JA, Holcenberg JS (1999) Clin Cancer Res 5: 3956-62 A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma. Atkins MB, Gollob JA, Sosman JA, McDermott DF, Tutin L, Sorokin P, Parker RA, Mier JW (2002) Clin Cancer Res 8: 3075-81
Hints: (1) double-click or double-tap to navigate to a node. (2) Grab a node and move it to arrange the graph.